Express Pharma
Home  »  Management  »  Newer therapies will steer Type II diabetes market in South-East Asia

Newer therapies will steer Type II diabetes market in South-East Asia

Read Article

The market will see a rise from $1.7 billion in 2015 to $2.7 billion by 2022, says GBI Research

The South-East Asian Type II diabetes mellitus (T2DM) market, which includes South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, will rise from $1.7 billion in 2015 to $2.7 billion by 2022, at a compound annual growth rate of 7.1 per cent, according to business intelligence provider GBI Research.

The company’s latest report states that as well as the rapidly expanding prevalence population in South-East Asia, market growth will be driven by the increased uptake of recently approved and emerging branded T2DM therapeutics, in favour of lower-cost generic products.

Aswini Nath, Analyst, GBI Research, explains, “Unmet needs relating to patient convenience and ease of use will be addressed significantly over the forecast period. Higher levels of innovation are apparent in the early-stage pipeline, which may lead to considerable improvements beyond the existing range of products, in terms of safety and efficacy in the long term.”

Nath said, “In terms of recently approved therapeutics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors have already achieved strong market uptake and are all expected to increase their market shares over the forecast period. In comparison with many previously marketed therapies, these new products provide improved weight control and lowered hypoglycemia risk.”

In terms of late-stage pipeline products with the potential to change the treatment paradigm, six candidates stand out as offering superior safety, efficacy, and patient compliance. These are Novo Nordisk’s NN-9535 (semaglutide subcutaneous formulation) and OG-217SC (semaglutide oral formulation) and Eli Lilly’s Trulicity (dulaglutide), which are GLP-1 receptor agonists; Merck’s ertugliflozin and Theracos’s bexagliflozin, which are SGLT-2 inhibitors; and Merck’s omarigliptin, which is a DPP-4 inhibitor.

Of these products, GBI Research believes that OG-217SC, being a first-to-market oral formulation in the GLP-1 agonist class of drug, has the most potential to change the treatment paradigm due to its improved administration route compared to other drugs in the same class.

However, Nath adds, “Although increased uptake of branded drugs is expected, metformin, a low-cost generic drug, will maintain its pivotal role in the T2DM treatment algorithm in South-East Asia. Due to its well-characterised safety and efficacy profiles, wide availability and low cost, metformin will continue to be prescribed as the first-line pharmacotherapy and also remain the favoured option for use in combination therapies.”

EP News BureauMumbai

Comments are closed.